Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GB-5001A
- Development stage
- Phase 1
- Lead developer
- G2GBio
- Modality
- Small Molecules
- Administration
- Intramuscular, Subcutaneous
01
Overview
GB-5001A is an investigational injectable formulation of donepezil, a small molecule acetylcholinesterase inhibitor. It is being developed as an intramuscular (IM) and subcutaneous (SC) depot injection. Donepezil is a well-established drug primarily used for the symptomatic treatment of Alzheimer's disease, where it works by increasing the concentration of acetylcholine in the brain, thereby enhancing cholinergic function and potentially improving cognitive symptoms. This formulation aims to evaluate the safety, tolerability, and pharmacokinetic characteristics of single-dose IM and SC administration.
- Other names
- donepezil injection
02
Targets
Acetylcholinesterase
Beyond the preview
Go deeper on GB-5001A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GB-5001A.